The global hospital infection therapeutics market size reached US$ 11.8 Billion in 2022. Looking forward, the analyst expects the market to reach US$ 15.8 Billion by 2028, exhibiting a growth rate (CAGR) of 4.8% during 2023-2028.
Hospital infection therapeutics refers to various pharmaceutical drugs used for the treatment of nosocomial infections. These infections can be acquired at hospitals, nursing homes, rehabilitation facilities and other clinical settings and are usually treated by antiviral, antibacterial and antifungal medicines. The antibacterial therapeutics consist of cell wall synthesis and protein synthesis inhibitors, such as vancomycin, carbapenems, cephalosporins, linezolid, aminoglycosides and tigecycline. The antifungal therapeutics include caspofungin and Amphotericin B. These drugs aid in preventing the instances of hospital-acquired pneumonia, urinary tract infections (UTIs), gastrointestinal disorders, bloodstream infections and surgical site infections.
The increasing prevalence of hospital-acquired diseases (HAD) is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. Resulting from the deterioration of hygiene facilities in hospitals and other healthcare institutions, there has been a significant increase in the occurrence of hospital-acquired pneumonia and other infections, which is contributing to the increasing demand for hospital infection therapeutics. Additionally, various product innovations, such as the development of advanced microbial wound care drugs, coverings and vaccines, are acting as other growth-inducing factors. Product manufacturers are developing antimicrobial drugs and pipeline drug molecules that are effective against multi-drug resistant infections and can be used for the treatment of infections with specific symptoms. Other factors, including extensive research and development (R&D) activities, along with improvements in the healthcare infrastructure, are expected to drive the market further.
Hospital infection therapeutics refers to various pharmaceutical drugs used for the treatment of nosocomial infections. These infections can be acquired at hospitals, nursing homes, rehabilitation facilities and other clinical settings and are usually treated by antiviral, antibacterial and antifungal medicines. The antibacterial therapeutics consist of cell wall synthesis and protein synthesis inhibitors, such as vancomycin, carbapenems, cephalosporins, linezolid, aminoglycosides and tigecycline. The antifungal therapeutics include caspofungin and Amphotericin B. These drugs aid in preventing the instances of hospital-acquired pneumonia, urinary tract infections (UTIs), gastrointestinal disorders, bloodstream infections and surgical site infections.
The increasing prevalence of hospital-acquired diseases (HAD) is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. Resulting from the deterioration of hygiene facilities in hospitals and other healthcare institutions, there has been a significant increase in the occurrence of hospital-acquired pneumonia and other infections, which is contributing to the increasing demand for hospital infection therapeutics. Additionally, various product innovations, such as the development of advanced microbial wound care drugs, coverings and vaccines, are acting as other growth-inducing factors. Product manufacturers are developing antimicrobial drugs and pipeline drug molecules that are effective against multi-drug resistant infections and can be used for the treatment of infections with specific symptoms. Other factors, including extensive research and development (R&D) activities, along with improvements in the healthcare infrastructure, are expected to drive the market further.
Key Market Segmentation
The report provides an analysis of the key trends in each sub-segment of the global hospital infection therapeutics market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on drug type and indication.Breakup by Drug Type:
- Anti-bacterial Drugs
- Anti-fungal Drugs
- Anti-viral Drugs
- Others
Breakup by Indication:
- Blood Stream Infections
- Urinary Tract Infections
- Surgical Site Infections
- Pneumonia
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape
The report has also analysed the competitive landscape of the market with some of the key players being Allergan Plc (AbbVie Inc.), AstraZeneca Plc, Bayer Aktiengesellschaft, Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc, Pfizer Inc. and Sanofi S.A.Key Questions Answered in This Report:
- How has the global hospital infection therapeutics market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global hospital infection therapeutics market?
- What are the key regional markets?
- What is the breakup of the market based on the drug type?
- What is the breakup of the market based on the indication?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global hospital infection therapeutics market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface3 Executive Summary10 Value Chain Analysis12 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Hospital Infection Therapeutics Market
6 Market Breakup by Drug Type
7 Market Breakup by Indication
8 Market Breakup by Region
9 SWOT Analysis
11 Porters Five Forces Analysis
13 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Allergan Plc (AbbVie Inc.)
- AstraZeneca Plc
- Bayer Aktiengesellschaft
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche AG (Roche Holding AG)
- Gilead Sciences Inc.
- GlaxoSmithKline plc
- Johnson & Johnson
- Merck & Co. Inc
- Pfizer Inc.
- Sanofi S.A.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 142 |
| Published | October 2023 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 11.8 Billion |
| Forecasted Market Value ( USD | $ 15.8 Billion |
| Compound Annual Growth Rate | 5.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
